FCCC LOGO Faculty Publications
Clark PE , Spiess PE , Agarwal N , Bangs R , Boorjian SA , Buyyounouski MK , Efstathiou JA , Flaig TW , Friedlander T , Greenberg RE , Guru KA , Hahn N , Herr HW , Hoimes C , Inman BA , Kader AK , Kibel AS , Kuzel TM , Lele SM , Meeks JJ , Michalski J , Montgomery JS , Pagliaro LC , Pal SK , Patterson A , Petrylak D , Plimack ER , Pohar KS , Porter MP , Sexton WJ , Siefker-Radtke AO , Sonpavde G , Tward J , Wile G , Dwyer MA , Smith C
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
J Natl Compr Canc Netw. 2016 Oct;14(10) :1213-1224
PMID: 27697976    PMCID: PMC5379654   
Back to previous list
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guerin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.
1540-1413 Clark, Peter E Spiess, Philippe E Agarwal, Neeraj Bangs, Rick Boorjian, Stephen A Buyyounouski, Mark K Efstathiou, Jason A Flaig, Thomas W Friedlander, Terence Greenberg, Richard E Guru, Khurshid A Hahn, Noah Herr, Harry W Hoimes, Christopher Inman, Brant A Kader, A Karim Kibel, Adam S Kuzel, Timothy M Lele, Subodh M Meeks, Joshua J Michalski, Jeff Montgomery, Jeffrey S Pagliaro, Lance C Pal, Sumanta K Patterson, Anthony Petrylak, Daniel Plimack, Elizabeth R Pohar, Kamal S Porter, Michael P Sexton, Wade J Siefker-Radtke, Arlene O Sonpavde, Guru Tward, Jonathan Wile, Geoffrey Dwyer, Mary A Smith, Courtney P30 CA006973/CA/NCI NIH HHS/United States P30 CA060553/CA/NCI NIH HHS/United States Guideline Journal Article United States J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.